Android app on Google Play

Analyst Cautiously Optimistic on ISIS (ISIS) SMN (Rx)

March 21, 2013 1:21 PM EDT Send to a Friend
Get Alerts ISIS Hot Sheet
Price: $31.62 +4.84%

Rating Summary:
    5 Buy, 6 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 27 | New: 8
Trade ISIS Now!
Join SI Premium – FREE
Leerink Swann today maintained a Market Perform rating on ISIS Pharmaceuticals (NASDAQ: ISIS) and boosted its price target to $18.00 (from $14.00). Analyst Joseph P. Schwartz said he believes that uncontrolled Phase I data for ISIS-SMN presented at the Annual American Academy of Neurology (AAN) meeting contained no surprises.

The raised price target reflects increased in the probability of success for SMN-Rx and TTR-Rx (both advancing to Phase III) to 85% from 33%.

For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.

Shares of ISIS Pharmaceuticals closed at $17.84 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Add Your Comment